

## Top ten research priorities for brain and spine cavernous malformations

Cavernous malformations, also known as cavernomas, affect people at any age and occur throughout the CNS. In the brain, they can cause haemorrhagic stroke<sup>1</sup> and epileptic seizures,<sup>2</sup> and in the spinal cord, they can bleed and cause myelopathy.<sup>3</sup> Despite the availability of microsurgical excision and stereotactic radiosurgery for cavernoma treatment and known genetic causes of most familial forms of cavernoma,<sup>4</sup> uncertainties remain about cause, diagnosis, prognosis, treatment, and care.

Therefore, to prioritise these uncertainties about brain and spine cavernomas for researchers and funding agencies,<sup>5</sup> we undertook a James Lind Alliance priority setting partnership. This partnership included a multidisciplinary steering group of patients, carers, health-care professionals, representatives of patient support organisations, an

information specialist, a James Lind Alliance adviser, and an administrator according to a protocol developed in August, 2014, and approved in January, 2015. The methods are described in full online.

Between January and March 2015, we gathered uncertainties using a web-based survey that was distributed by professional and support organisations in the UK via email, post, and social media to patients, carers, and health-care professionals. We received 2268 uncertainties from 299 respondents (63% patients, 18% health-care professionals, and 19% others), and identified a further 34 uncertainties from searches of the scientific literature. An information specialist subsequently de-duplicated these submissions, rejected submissions that were out of the scope of the priority setting partnership, rejected uncertainties if there was evidence in published systematic reviews that they had been answered, and added uncertainties identified by these systematic reviews, resulting in a long list of 79 unique uncertainties. The steering

group worked in pairs to further shorten the list to 54 uncertainties, which we circulated to 246 survey respondents who chose priorities from the long list of uncertainties. 136 (55%) respondents participated in the web-based prioritisation exercise, in which we used the rank order technique to generate a short list of 31 uncertainties. At a final in-person workshop including 29 participants (41% patients, 31% health-care professionals, and 28% others) and facilitated by three James Lind Alliance advisers, we achieved consensus on a final list of 27 uncertainties (listed in the UK Database of Uncertainties about the Effects of Treatments [DUETs]), of which the top ten are immediate priorities for future research (panel).


The top ten uncertainties reflect the concerns of patients, carers, and health-care professionals in the UK: five concerned prognosis, three concerned treatment or care, and two concerned cause. The James Lind Alliance process assures the internal validity and reliability of these priorities, but their generalisability to other populations is unknown. The 27 uncertainties identified by this priority setting partnership, and in particular the top ten, can now inform the projects that the research community pursue and that funding bodies support in the UK and perhaps other parts of the world.

We declare no competing interests. This project was supported by funding from The Hospital Saturday Fund, the Lothian Healthboard Endowment Fund, The National Hospital Development Foundation, and members of Cavernoma Alliance UK. The work presented here represents the views of the authors and not necessarily those of the funding bodies.

*\*Rustam Al-Shahi Salman, Neil Kitchen, Jennifer Thomson, Vijeya Ganesan, Conor Mallucci, Matthias Radatz, for the Cavernoma Priority Setting Partnership Steering Group*

[psp@cavernoma.org.uk](mailto:psp@cavernoma.org.uk)

Centre for Clinical Brain Sciences, Chancellor's Building, University of Edinburgh, Edinburgh EH16 4SB, UK (RA-SS); National Hospital for Neurology and Neurosurgery, Queen Square, London, UK (NK);



Living Art Enterprises, LLC/Science Photo Library

*Lancet Neurol* 2016

Published Online  
January 29, 2016  
[http://dx.doi.org/10.1016/S1474-4422\(16\)00039-9](http://dx.doi.org/10.1016/S1474-4422(16)00039-9)

For more on the James Lind Alliance see <http://www.jla.nihr.ac.uk/priority-setting-partnerships/cavernoma>

For the priority setting partnership methods see <https://www.cavernoma.org.uk/our-projects-and-campaigns/priority-setting-partnership-psp-project/>

For DUETs see <http://www.library.nhs.uk/duets/SearchResults.aspx?tabID=294&catID=15622>

### Panel: Top ten research priorities for cavernous malformations (cavernomas)

- 1 Does treatment (with neurosurgery or stereotactic radiosurgery) or no treatment improve outcome for people diagnosed with brain or spine cavernoma?
- 2 How do brain or spine cavernomas start and develop?
- 3 What is the risk of brain or spine cavernomas bleeding for the first and subsequent times?
- 4 Could drugs targeted at cavernomas improve outcome for people with brain or spine cavernomas compared to no drug treatment?
- 5 What mechanisms trigger bleeding or epileptic seizures in people with brain or spine cavernomas?
- 6 Are any features of brain or spine cavernoma on imaging associated with a higher or lower risk of bleeding?
- 7 Does the use of anticoagulant drugs increase the risk of bleeding from brain or spine cavernoma?
- 8 Does regular monitoring of brain or spine cavernoma improve outcome compared to no monitoring?
- 9 What features of brain cavernoma lead to the development of epilepsy or influence the severity of existing epilepsy?
- 10 Do any specific activities undertaken by people with brain or spine cavernomas provoke bleeds or other symptoms?

Yorkshire Regional Clinical Genetics Service, Chapel Allerton Hospital, Harehills Lane, Leeds, UK (JT); UCL Institute of Child Health, London, UK (VG); Alder Hey Children's NHS Foundation Trust, Eaton Road, West Derby, Liverpool, UK (CM); and National Centre for Stereotactic Radiosurgery, Royal Hallamshire Hospital, Glossop Road, Sheffield, UK (MR)

- 1 Horne MA, Flemming KD, Su I-C, et al, and the Cerebral Cavemous Malformations Individual Patient Data Meta-analysis Collaborators. Clinical course of untreated cerebral cavernous malformations: an individual patient data meta-analysis. *Lancet Neurol* 2016; **15**: 166–73.
- 2 Rosenow F, Alonso-Vanegas MA, Baumgartner C, et al, and for the Surgical Task Force, Commission on Therapeutic Strategies of the ILAE. Cavemoma-related epilepsy: review and recommendations for management: report of the Surgical Task Force of the ILAE Commission on Therapeutic Strategies. *Epilepsia* 2013; **54**: 2025–35.
- 3 Badhiwala JH, Farrokhyar F, Alhazzani W, et al. Surgical outcomes and natural history of intramedullary spinal cord cavernous malformations: a single-center series and meta-analysis of individual patient data: clinic article. *J Neurosurg Spine* 2014; **21**: 662–76.
- 4 Labauge P, Denier C, Bergametti F, Tournier-Lasserre E. Genetics of cavernous angiomas. *Lancet Neurol* 2007; **6**: 237–44.
- 5 Chalmers I, Bracken MB, Djulbegovic B, et al. How to increase value and reduce waste when research priorities are set. *Lancet* 2014; **383**: 156–56.